Prescription co-pay reduction program for diabetic employees

Population Health Management

Volumn 13, Issue 5, 2010, Pages 235-245

  Nair, Kavita V ^a   Miller, Kerri ^b   Park, Jinhee ^c   Allen, Richard R ^d   Saseen, Joseph J ^a   Biddle, Vinita ^e  

^a UNIVERSITY OF COLORADO   (United States)

^b Pharmaceutical Strategies Group Consultants   (United States)

^c GLAXOSMITHKLINE   (United States)

^d Peak Statistical Services   (United States)

^e State of Colorado   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GENERIC DRUG;

ADULT; AGE; ARTICLE; COMORBIDITY; COST CONTROL; DIABETES MELLITUS; DIABETIC PATIENT; DRUG COST; DRUG UTILIZATION; EMERGENCY TREATMENT; EMPLOYEE; EMPLOYER; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHARMACY; PRESCRIPTION; SEX;

ADULT; AGED; DIABETES MELLITUS; FEMALE; HEALTH EXPENDITURES; HUMANS; HYPOGLYCEMIC AGENTS; INSURANCE BENEFITS; INSURANCE, PHARMACEUTICAL SERVICES; LIKELIHOOD FUNCTIONS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POISSON DISTRIBUTION; PRESCRIPTION DRUGS; PROGRAM DEVELOPMENT; PROGRAM EVALUATION; RISK ASSESSMENT; UNITED STATES;

EID: 77957746087     PISSN: 19427891     EISSN: 19427905     Source Type: Journal    
DOI: 10.1089/pop.2009.0066     Document Type: Article

References (25)

1. Cramer JA. A systematic review of adherence with diabetic medications. Diabetes Care 2004;27:1218-1224.
2. Austvoll-Dahlgren A, Aaserud M, Vist GE, et al. Pharmaceutical policies: Effects of cap and co-payment on rational drug use. Cochrane Database Syst Rev 2008;1: CD007017.
3. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost sharing among poor and elderly persons. JAMA 2001;285:421-429.
4. Motheral B, Fairman KA. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care 2001;39:1293-1304.
5. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: Associations with medication and medical utilization and spending and health. JAMA 2007;298:61-69.
6. Fendrick AM, Chernew ME. Value-based insurance design: Aligning incentives to bridge the divide between quality improvement and cost containment. Am J Manag Care 2006;12: SP5-SP10.
7. Fitch K, Iwaski K, Pyenson B. Value-based insurance designs for diabetic drug therapy: Actuarial and implementation considerations. Available at: http://www.milliman.com/expertise/healthcare/publications/rr/pdfs/ vbid-diabetes-drug-therapy-RR12-01-08.pdf. Accessed February 3, 2010.
8. Chernew M, Fendrick AM. Value and increased cost sharing in the American health care system. Health Serv Res 2008;43:451-457.
9. Reuters. MBGH annual employer benefit survey reveals growing shift to value-based benefit design. Available at: http://www.reuters.com/article/ pressRelease/idUS127367 + 01-May-2008+PRN20080501. Accessed June 30, 2008.
10. Cranor CW, Bunting BA, Christensen DB. The Asheville Project: Long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc 2003;43:173-184.
11. Odegard PS, Goo A, Hummel J, Williams KL, Gray SL. Caring for poorly controlled diabetes mellitus: A randomized pharmacist intervention. Ann Pharmacother 2005;39:433-440.
12. Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care 2005;11: S170-S176.
13. Chernew ME, Shah MR, Wegh A, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff (Millwood). 2008;27:103-112.
14. Nair KV, Miller K, Saseen JJ, Wolfe P, Allen RR, Park J. Prescription copay reduction program for diabetic employees: Impact on medication compliance and healthcare costs and utilization. Am Health Drug Benefits 2009;2:14-24.
15. Chronic condition data warehouse. Research Assistant Data Center (ResDAC). Available at: http://www.ccwdata.org/downloads/CCW%20User%20Manual. pdf. Accessed June 30, 2008.
16. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12.
17. Robst J, Levy JM, Ingber MJ. Diagnosis-based risk adjustment for Medicare prescription drug plan payments. Health Care Financ Rev 2007;28:15-30.
18. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
19. University of Michigan. M Healthy focus on diabetes. Available at: http://hr.umich.edu/mhealthy/programs/disease/diabetes.html. Accessed November 20, 2009.
20. Fera T, Blumi BM, Ellis WM. Diabetes Ten City Challenge: Final economic and clinical results. J Am Pharm Assoc 2009;49:383-391.
21. Nau DP, Aikens JE, Pacholski AM. Effects of gender and depression on oral medication adherence in persons with type 2 diabetes mellitus. Gend Med 2007;4:205-213.
22. Pauly MV. The economics of moral hazard: comment. Am Econ Rev 1968;58:531-537.
23. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-530.
24. Linden A, Adams JL, Roberts N. Evaluation methods in disease management: Determining program effectiveness. Available at: http://www.dmaa.org/pdf/ Evaluation-Methods-in-DM.pdf. Accessed November 20, 2009.
25. Rowland C, Krasner J. $4 drug program imitated, criticized. Specialists see limited impact. Available at: http://www.boston.com/business/ globe/articles/2006/11/17/4-drug-program-imitated-criticized/. Accessed February 4, 2010.